Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico

Guhl, Guillermo; Arriba, A. González-de; Daudén, E.

doi:10.1016/s0001-7310(06)73407-x

Cited by 25 publications

(8 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interruption of this anticancer treatment is mandatory in severe cases . Anti‐EGFR antibodies, besides downregulating proliferative/survival stimuli , induce leucocyte infiltration, thus contributing to skin toxicity .…”

Section: Background and Premisesmentioning

confidence: 99%

“…Anticancer agents that inhibit EGFR have been applied to solid tumors in advanced stages (1)(2)(3)(4), having better tolerance than conventional chemotherapy (5). Monoclonal antibodies (mAb) cetuximab and panitumumab (6)(7)(8) are used for the treatment of metastatic colorectal cancer (mCRC), but papulopustular rash occurs as a common side effect in more than 80% of the patients (1,(9)(10)(11). Interruption of this anticancer treatment is mandatory in severe cases (2,7,10).…”

Section: Background and Premisesmentioning

confidence: 99%

See 1 more Smart Citation

Association between EGFR gene polymorphisms, skin rash and response to anti‐EGFR therapy in metastatic colorectal cancer patients

Jaka

Gutiérrez-Rivera

Ormaechea

et al. 2014

Experimental Dermatology

View full text Add to dashboard Cite

Cetuximab and panitumumab are epidermal growth factor receptor (EGFR) inhibitors used in metastatic colorectal cancer (mCRC). Most patients develop a papulopustular rash that may predict tumor response to treatment. EGFR gene polymorphisms may also determine tumor response and appearance of skin rash. We hypothesized an association between EGFR gene polymorphisms, papulopustular rash and response to anticancer treatment. Four EGFR polymorphisms (À216, À191, CA-SSR, R521K) were analysed in 51 patients with mCRC receiving anti-EGFR. Severity of cutaneous rash and tumor response was measured following standard scales. We report an association between SNP-216 and tumor response (P = 0.003): no tumor progression occurred in TT genotype. Moreover, 92.3% of the responder patients developed skin rash, 62.9% of them presenting a grade ≥2 (P = 0.015). Thus, although underpowered, our preliminary data suggest that SNP-216 polymorphism of the EGFR gene could be useful in predicting tumor response and the appearance of severe skin rash might also be associated.

show abstract

Section: Background and Premisesmentioning

confidence: 99%

Section: Background and Premisesmentioning

confidence: 99%

Association between EGFR gene polymorphisms, skin rash and response to anti‐EGFR therapy in metastatic colorectal cancer patients

Jaka

Gutiérrez-Rivera

Ormaechea

et al. 2014

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Walon et al 20 ya proponían en el año 2003 la inclusión del cetuximab en la lista de medicamentos susceptibles de inducir erupción acneiforme a propósito de 2 casos. Posteriores revisiones [5][6][7][8][9] evaluaban la incidencia y el tipo de reacciones que se presentan en los pacientes que reciben tratamiento, relacionándolas con una línea de tiempo y con la eficacia del tratamiento. Si revisamos la literatura médica, este exantema cutáneo ha recibido muy diferentes denominaciones: exantema acneiforme, exantema maculopapuloso, exantema acné-like, foliculitis, etc.…”

Section: Fisuras Paroniquiaunclassified

“…No obstante, estos compuestos se asocian con una gran variedad de efectos adversos dermatológicos de alta prevalencia, en particular, el cetuximab. Este receptor también se expresa en la lámina basal de la epidermis donde estimula el crecimiento de la misma, inhibe la diferenciación y acelera la cicatrización de heridas [5][6][7][8][9][10] . El bloqueo por parte del anticuerpo en células de la epidermis lleva a reacciones adversas como erupciones acneiformes, alteraciones del cuero cabelludo y crecimiento del pelo, trastornos ungueales y oculares, xerosis y prurito.…”

Section: Introductionunclassified

See 1 more Smart Citation

Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico

Rodriguez-Murphy

Villanueva-Herraiz

Ortega-García

et al. 2011

Farmacia Hospitalaria

View full text Add to dashboard Cite

Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach

Gobbo¹,

Ottaviani²,

Mustacchi³

et al. 2011

Lasers Med Sci

View full text Add to dashboard Cite

Acneiform rash associated with epidermal growth factor receptor inhibitors frequently presents facial manifestations. The treatment modality for such lesions still needs to be elucidated. The aim of this original report was to evaluate the effectiveness of high-level laser therapy in reducing the severity of facial acneiform rash induced by cetuximab, an epidermal growth factor receptor inhibitors. Four patients with metastatic colorectal cancer and two patients with head and neck cancer showing cetuximab-induced facial rash were treated by high-level laser therapy in two 8-min-long consecutive sessions/day over a 4-day treatment. Patients wore protective glasses to prevent eye damage related to laser light. Subsequently, patients were seen once a week for up to 21 days and after 180 days. During each day of treatment and each follow-up recall, patients were asked to complete a questionnaire about the onset and progression of their acneiform rash (for a total of eight sessions). Cetuximab-related toxicity and general discomfort visual analogue scales were also recorded in each of these eight sessions in the treated and control areas in each patient. After the fourth session of high-level laser therapy, the patients showed a noteworthy decrease in both cetuximab-related toxicity and visual analogue scales, up to a complete regression of the lesions at the end of the follow-up in all treated areas. The high-level laser therapy was effective in the healing of acneiform rash associated with epidermal growth factor receptor inhibitors with no side effects.

show abstract

Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico

Cited by 25 publications

References 97 publications

Association between EGFR gene polymorphisms, skin rash and response to anti‐EGFR therapy in metastatic colorectal cancer patients

Association between EGFR gene polymorphisms, skin rash and response to anti‐EGFR therapy in metastatic colorectal cancer patients

Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico

Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach

Contact Info

Product

Resources

About